Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
Summit Therapeutics presented encouraging Phase II data for ivonescimab in first-line metastatic colorectal cancer at ASCO 2026. The study showed a 70.8% objective response rate and 100% disease control rate in patients receiving ivonescimab plus mFOLFOX6 chemotherapy, with a favorable safety profile comparable to standard anti-VEGF regimens.
Key figures
- Drug Name
- ivonescimab
- Phase Of Trial
- Phase II
- Dcr
- 100.0%
- Orr
- 70.8%
- Patient count
- 49
- Serious trae rate
- 20.4%
- Dor landmark 9mo 10mg
- 41.5%
- Dor landmark 9mo 20mg
- 79.1%
- Pfs landmark 9mo 20mg
- 76.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.